시장보고서
상품코드
1267446

차세대 암 진단 : 각종 기술과 세계 시장

Next-Generation Cancer Diagnostics: Technologies and Global Markets

발행일: | 리서치사: BCC Research | 페이지 정보: 영문 166 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 암 진단 시장 규모는 2022년 87억 달러에서 2022년부터 2027년까지 11.5%의 CAGR을 나타내고, 2027년에는 150억 달러 규모로 성장할 것으로 예측됩니다.

유방암 부문은 2022년 22억 달러에서 11.6%의 CAGR을 나타내고, 2027년에는 39억 달러 규모로 성장할 것으로 예측됩니다. 또한 비뇨기계 부문은 2022년 6억 1,040만 달러에서 14.5%의 CAGR을 나타내고, 2027년에는 12억 달러 규모로 성장할 것으로 예측됩니다.

세계의 차세대 암 진단 시장을 조사했으며, 시장 및 기술 배경, 시장 규모 추정과 예측, 각종 부문·지역별 상세 분석, 특허 동향, 시장 영향요인 분석, 경쟁 환경, 주요 기업 개요 등을 정리했습니다.

목차

제1장 서론

제2장 요약과 하이라이트

제3장 시장 및 기술 배경

  • 개요
  • 맞춤형 의료의 차세대 시퀀싱
  • 임상 종양학의 NGS
  • 대규모 이니셔티브와 컨소시엄
  • 액체생검 기술
  • 시장을 견인하는 액체생검
  • 산업
  • 진단 개요
  • 어레이 및 마이크로플루이딕스(LOAC) 기술
  • 기존 기술의 다중화
  • 중합효소 연쇄 반응(PCR) 기술

제4장 암 진단 시장

  • 성장 촉진요인
  • 암 시장
  • 차세대 암 진단 시장 : 암 부위별
    • 방광암
    • 뇌종양
    • 유방암
  • 차세대 암 진단 시장 : 분석 목적별
    • 스크리닝·조기 발견
    • 진단
    • 치료 지도
    • 감시
  • 차세대 암 진단 시장 : 검사 플랫폼별
    • PCR 검사 플랫폼
    • NGS 검사 플랫폼
    • 어레이/마이크로플루이딕스 검사 플랫폼
    • 세포 및/또는 EV 캡처 검사 플랫폼
    • 멀티플렉스 기존 검사 플랫폼
  • 검사 플랫폼 시장 : 암 부위별
    • PCR 검사 플랫폼
    • NGS 검사 플랫폼
  • 진단 구분별 시장
    • 스크리닝·조기 발견
    • 진단
    • 감시
    • 치료 지도
    • 유방암 진단
    • 소화기암 진단
    • 호흡기암 및 피부암 진단

제5장 시장 내역 : 암 부위·용도별

  • 개요
  • 방광암
  • 뇌종양
  • 유방암
  • 부인과암
    • 자궁경부암
    • 난소암
  • 대장암
  • 원발불명암
  • 위암
  • 신장암
  • 혈액 검사 : 백혈병 및 골수종
  • 간암
  • 폐암
  • 혈액 검사 : 림프종
  • 흑색종
  • 범암
  • 전립선암
  • 갑상선암

제6장 신기술

  • 개요
  • 집단 시퀀싱 프로그램
  • CRISPR

제7장 시장 평가 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제8장 특허

제9장 기업 개요

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES
  • ARTIVION INC.
  • BECTON, DICKINSON AND CO.
  • BENITEC BIOPHARMA LTD.
  • CALADRIUS BIOSCIENCES
  • CELGENE CORP.
  • COMMENCE BIO
  • DEPUY SYNTHES(J&J)
  • DRAGERWERK AG & CO. KGAA
  • EPIC SCIENCES INC.
  • GENEXINE
  • GERON
  • ILLUMINA INC.
  • IMMUNOCELLULAR THERAPEUTICS
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVIVOSCRIBE INC.
  • MEDTRONIC PLC
  • MERCK KGAA
  • NOVARTIS AG
  • ONCOCYTE CORP.
  • ONCOMED PHARMACEUTICALS INC.
  • PLURISTEM THERAPEUTICS INC.
  • SILICON BIOSYSTEMS S.P.A
  • SPHERE FLUIDICS LTD.
  • THERMO FISHER SCIENTIFIC
  • VITATEX INC.
KSM 23.05.11

Highlights:

The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.

Breast segment of the global next-generation cancer diagnostics market reached $2.2 billion in 2022 and should reach $3.9 billion by 2027, with a CAGR of 11.6% during the forecast period of 2022-2027.

Urinary system segment of the global next-generation cancer diagnostics market reached $610.4 million in 2022 and should reach $1.2 billion by 2027, with a CAGR of 14.5% during the forecast period of 2022-2027.

Report Scope:

This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.

An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.

The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).

The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.

Report Includes:

  • 15 data tables and 80 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
  • Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
  • Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Study Goals and Objectives
  • 1.2 Reasons for Doing This Study
  • 1.3 Scope of Report
  • 1.4 What's New in This Update?
  • 1.5 Information Sources and Methodology
    • 1.5.1 Secondary Research
    • 1.5.2 Primary Research
  • 1.6 Research Methodology
  • 1.7 Geographic Breakdown
  • 1.8 Analyst's Credentials
  • 1.9 BCC Custom Research
  • 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • 3.1 Overview
  • 3.2 Next Generation Sequencing in Personalized Medicine
    • 3.2.1 Cost-Effective
    • 3.2.2 Samples Required
  • 3.3 NGS in Clinical Oncology
    • 3.3.1 Accurate Detection of Genetic Mutations
    • 3.3.2 Precision Diagnostics
    • 3.3.3 Tumor Genomic Profiling
  • 3.4 Large-Scale Initiatives and Consortia
  • 3.5 Liquid Biopsy Technologies
  • 3.6 Liquid Biopsy as a Market-Driving Force
    • 3.6.1 Key Trends
  • 3.7 Industry
  • 3.8 Diagnostics Overview
  • 3.9 Arrays and Microfluidics (LOAC) Technologies
    • 3.9.1 DNA Microarrays
    • 3.9.2 Protein Microarrays
    • 3.9.3 Microfluidics
  • 3.10 Multiplex Conventional Technologies
  • 3.11 Polymerase Chain Reaction (PCR) Technology

Chapter 4 Cancer Diagnostics Market

  • 4.1 Forces Driving Growth
  • 4.2 Cancer Markets
  • 4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site
    • 4.3.1 Bladder Cancer
    • 4.3.2 Brain Cancer
    • 4.3.3 Breast Cancer
  • 4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis
    • 4.4.1 Screening/Early Detection Market
    • 4.4.2 Diagnostics Market
    • 4.4.3 Therapy Guidance Market
    • 4.4.4 Monitoring Market
  • 4.5 Market for Next-Generation Cancer Diagnostics by Test Platform
    • 4.5.1 PCR Test Platform
    • 4.5.2 NGS Test Platform
    • 4.5.3 Array/Microfluidics Test Platform
    • 4.5.4 Cells and/or EV Capture Test Platform
    • 4.5.5 Multiplex Conventional Test Platform
  • 4.6 Market for Test Platforms by Cancer Site
    • 4.6.1 PCR Test Platform
    • 4.6.2 NGS Test Platform
  • 4.7 Market by Diagnostic Segment
    • 4.7.1 Screening/Early Detection Market
    • 4.7.2 Diagnostics Market
    • 4.7.3 Monitoring Market
    • 4.7.4 Therapy Guidance Market
    • 4.7.5 Breast Cancer Diagnostics
    • 4.7.6 Digestive Cancer Diagnostics
    • 4.7.7 Respiratory and Skin Cancer Diagnostics

Chapter 5 Market Breakdown Application by Cancer Site

  • 5.1 Overview
  • 5.2 Bladder Cancer
  • 5.3 Brain Cancer
    • 5.3.1 Types of Brain Cancer
  • 5.4 Breast Cancer
    • 5.4.1 Risk
    • 5.4.2 Breast Cancer Screening
    • 5.4.3 Prognosis and Pharmacogenetics Tests
    • 5.4.4 Breast Cancer MDx Platforms
    • 5.4.5 Status of Next-Generation Breast Cancer Tests
    • 5.4.6 Treatment
  • 5.5 Gynecologic Cancers
    • 5.5.1 Cervical Cancer
    • 5.5.2 Ovarian Cancer
  • 5.6 Colorectal Cancer
    • 5.6.1 Conventional Colorectal Cancer Screening Tests
    • 5.6.2 Next-Generation Colorectal Cancer Diagnostic Tests
  • 5.7 Cancer Unknown Primary
  • 5.8 Gastric Cancer
  • 5.9 Kidney Cancer
  • 5.10 Hematologic Tests: Leukemia and Myeloma
  • 5.11 Liver Cancer
  • 5.12 Lung Cancer
  • 5.13 Hematologic Tests: Lymphomas
  • 5.14 Melanoma
  • 5.15 Pan-Cancer
  • 5.16 Prostate Cancer
  • 5.17 Thyroid Cancer

Chapter 6 Emerging Technologies

  • 6.1 Overview
  • 6.2 Population Sequencing Programs
  • 6.3 Introduction
  • 6.4 CRISPR

Chapter 7 Evaluation of the Market Based on Geographic Region

  • 7.1 Overview of the Geographical Distribution of the Market
  • 7.2 Overview
  • 7.3 North America
  • 7.4 Europe
  • 7.5 Asia-Pacific
  • 7.6 Rest of the World

Chapter 8 Patents

Chapter 9 Company Profiles

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES
  • ARTIVION INC.
  • BECTON, DICKINSON AND CO.
  • BENITEC BIOPHARMA LTD.
  • CALADRIUS BIOSCIENCES
  • CELGENE CORP.
  • COMMENCE BIO
  • DEPUY SYNTHES (J&J)
  • DRAGERWERK AG & CO. KGAA
  • EPIC SCIENCES INC.
  • GENEXINE
  • GERON
  • ILLUMINA INC.
  • IMMUNOCELLULAR THERAPEUTICS
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVIVOSCRIBE INC.
  • MEDTRONIC PLC
  • MERCK KGAA
  • NOVARTIS AG
  • ONCOCYTE CORP.
  • ONCOMED PHARMACEUTICALS INC.
  • PLURISTEM THERAPEUTICS INC.
  • SILICON BIOSYSTEMS S.P.A
  • SPHERE FLUIDICS LTD.
  • THERMO FISHER SCIENTIFIC
  • VITATEX INC.
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제